Biomedtracker / Meddevicetracker Q3 2020 Outlook Report

New York, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Biomedtracker / Meddevicetracker Q3 2020 Outlook Report" - https://www.reportlinker.com/p05955632/?utm_source=GNW
These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker. The results of the drug catalysts highlighted in our Biomedtracker / Meddevicetracker Q2 2020 Outlook Report can be found on Page 6. At the end of this report, we have included a list of Large Impact catalysts through Q3 2020.
Indications Covered
Acne
Acute Myelogenous Leukemia (AML)
Angelman Syndrome
Bipolar Disorder
Cardiac Valve Surgery
COVID-19
Diffuse Large B-Cell Lymphoma (DLBCL) - NHL
Graft vs. Host Disease (GVHD) - Treatment
Hemophilia A
Hyperoxaluria
Ischemic Stroke
Major Depressive Disorder (MDD)
Mantle Cell Lymphoma - NHL
Multiple Myeloma (MM)
Multiple Sclerosis (MS)
Myelodysplastic Syndrome (MDS)
Osteoarthritis and Osteoarthritis Pain
Other Ophthalmological Indications (Ophthalmology)
Renal Disease / Renal Failure
Rheumatoid Arthritis (RA)
Scleroderma
Seizure Disorders (Epilepsy)
Spinal Muscular Atrophy
Read the full report: https://www.reportlinker.com/p05955632/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001